Dehns | European Union, United Kingdom | 10 Nov 2022
Dehns have previously discussed the concept of plausibility and how much experimental data is needed for patent applications in Europe, which is…
Dehns | United Kingdom | 1 Nov 2022
The time and financial expense of bringing a novel drug to market is enormous and the process is fraught with risk. Very often, a putative novel…
Audio
Dehns | United Kingdom | 27 Oct 2022
In this episode of The IP Podcast, Senior Associate Daniel Rowe discusses a topic relating to the biotechnology and pharma industries: repurposed…
Dehns | European Union | 25 Oct 2022
The time and financial expense of bringing a novel drug to market is enormous and the process is fraught with risk. Very often, a putative novel…
Dehns | European Union, United Kingdom | 13 Oct 2022
One area in which European patent law lacks clarity is how far a commercial product placed on the market becomes part of the state of the art. Whilst…
Dehns | European Union, United Kingdom | 28 Sep 2022
The purpose of patents is to drive innovation. However, many jurisdictions accept that a patent term of 20 years from filing is not always sufficient…
Dehns | European Union, United Kingdom | 21 Sep 2022
A key test for assessing whether an invention has been sufficiently disclosed in Europe is one of plausibility: has the invention…